http://www.acc.org/Feed?clinicalTopicID=5f25c4ac-b76f-4970-a93c-15cdf264bed5 Clinical Topic Feed: Dyslipidemia en /Latest-in-Cardiology/Articles/2026/08/10/13/07/cardiacast_10aug2026 This episode of CardiaCast will feature a discussion on risk assessment and genetics in the prevention of cardiovascular disease. 1786367400000 Articles and Stories /Latest-in-Cardiology/Articles/2026/08/04/15/47/cardiacast_07aug2026 This episode of CardiaCast will feature a discussion on risk assessment and the treatment of hypertriglyceridemia. 1786111200000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/08/05/20/14/GBD-Study-2023 The global burden attributable to elevated LDL-C has grown substantially since 1990, driven largely by population growth and aging despite significant declines in age-standardized rates, according to findings from the Global Burden of Disease Study 2023 (GBD 2023) Cholesterol Collaborators published July 29 in JAMA. 1786042800000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/08/03/10/06/ADVANCE-OUTCOMES Ralinepag, a selective prostacyclin IP receptor agonist, significantly reduced the risk of first clinical worsening compared with placebo in patients with pulmonary arterial hypertension (PAH) but was associated with more adverse-event-related treatment discontinuations, according to results of the ADVANCE OUTCOMES trial published July 28 in The Lancet. 1785862800000 Articles and Stories /Latest-in-Cardiology/Articles/2022/01/01/01/01/ACC-Featured-Jobs Ready to explore a new professional opportunity? Browse the list below of featured jobs and take the next step in your career! 1785581280000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/07/28/17/19/NHANES-Analyses Three studies using National Health and Nutrition Examination Survey (NHANES) data published July 20 in JAMA provide new insights into LDL-C treatment goals under the 2026 ACC/AHA Guideline on the Management of Dyslipidemia. 1785351240000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/07/20/14/38/GBD-2023 Nearly 90% of ischemic heart disease (IHD) deaths in 2023 in the U.S. were attributable to modifiable risk factors, led by high systolic blood pressure (SBP), dietary risks and high LDL-C, according to data from the Global Burden of Disease Study 2023 (GBD 2023), published July 15 in JAMA Cardiology. 1784735640000 Articles and Stories /Latest-in-Cardiology/Articles/2026/07/21/12/01/FDA-Update The U.S. Food and Drug Administration (FDA) has approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, to lower LDL cholesterol in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). 1784635560000 Articles and Stories /Latest-in-Cardiology/Articles/2026/07/17/13/59/cardiacast_20jul2026 This episode of CardiaCast will feature a discussion on the treatment of atherosclerotic cardiovascular disease (ASCVD) risk – from lifestyle to advanced therapies, led by Dr. Maya Safarova. 1784553360000 Articles and Stories /Latest-in-Cardiology/Articles/2026/07/01/12/47/eagles-eye-view-01jul2026 In this week’s View, Dr. Eagle looks at how genotype independently predicts heart failure outcomes in patients with hypertrophic cardiomyopathy (HCM). 1782910140000 Articles and Stories